IL-1β, IL-6, and TNF gene polymorphisms do not affect the treatment outcome of rheumatoid arthritis patients with leflunomide

被引：0
作者：
Andrzej Pawlik
Magdalena Herczyńska
Mateusz Kurzawski
Krzysztof Safranow
Violetta Dziedziejko
Zygmunt Juzyszyn
Marek Droździk
机构：
[1] Pomeranian Medical University,Department of Pharmacology
[2] County Hospital,Department of Rheumatology
[3] Pomeranian Medical University,Department of Biochemistry and Medical Chemistry
来源：
Pharmacological Reports | 2009年 / 61卷
关键词：
rheumatoid arthritis; leflunomide; cytokines; polymorphism;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Leflunomide is an isoxazole derivative that is structurally and functionally unrelated to other known immunomodulatory drugs. Previous studies have revealed that therapy with leflunomide causes decreased production of mediators such as IL-1β, IL-6, and TNF-α, which are involved in inflammatory process. The aim of the present study was to examine whether the polymorphisms in genes IL1B, IL6, and TNF may affect treatment outcomes in RA patients treated with leflunomide.
引用
收藏
页码：281 / 287
页数：6
相关论文
共 142 条
[1]  
Bartnicka L(2007)Effect of ABCB1 (MDR1) 3435C >T and 2677G >A, T polymorphisms and P-glycoprotein inhibitors on salivary digoxin secretion in congestive heart failure patients Pharmacol Rep 59 323-329
[2]  
Kurzawski M(1996)Molecular mechanisms of action of new xenobiotic immunosuppressive drugs: tacrolimus (FK506), sirolimus (rapamycin), mycophenolate mofetil and leflunomide Curr Opin Immunol 8 710-720
[3]  
Droździk A(2003)The active metabolite of leflunomide, A77 1726, inhibits the production of prostaglandin E(2), matrix metalloproteinase 1 and interleukin 6 in human fibroblast-like synoviocytes Rheumatology 42 89-96
[4]  
Płońska-Goœciniak E(2006)Thiopurine S-methyltransferase phenotype-genotype correlation in hemodialyzed patients Pharmacol Rep 58 973-978
[5]  
Górnik W(1996)The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase Biochemistry 35 1270-1273
[6]  
Droździk M(2003)Active leflunomide metabolite inhibits interleukin 1β, tumour necrosis factor α, nitric oxide, and metalloproteinase-3 production in activated human synovial tissue cultures Ann Rheum Dis 62 440-443
[7]  
Brazelton TR(2002)Severe pyridine nucleotide depletion in fibroblasts from Lesch-Nyhan patients Biochem J 366 265-272
[8]  
Morris RE(1995)American College of Rheumatology Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 38 727-735
[9]  
Burger D(1993)The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum 36 729-740
[10]  
Begué-Pastor N(2000)Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases Immunopharmacology 47 273-289
12345678910